Media Update, page-1498

I hope they're not tbh, or at least just get the RAT registered on the ARTG as acceptable first. Then, once they've sold some initial devices, lodge an amendment down the track to have the sensitivity re-evaluated when/if ACCESSBIO has supplied us with the supporting data indicating a higher sensitivity level.

As I've said before the reasons for delay will be the elephant in the room at the 2nd Q update from AT1. Even if we recieve approval prior to the teleconference of the 2nd Q results I hope we as shareholders hold JK accountable by answering our concerns around the application process.